Altoida Medical Device (AMD) is a class II medical device to screen and monitor cognitive outcomes. It supports neurologists to classify patients healthy, at risk, and with Mild Cognitive Impairment (MCI) as a digital biomarker.

Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance, and is indicated for use as an adjunctive tool to aid in evaluation perceptual and memory function in patients 55 to 95 years old. AMD is a FDA class II medical device enabling:

Using an augmented reality framework that allows performing tests on complex everyday tasks while directly interacting with a user's environment and thus physically activate him, we are testing three major areas:

Instruction to go from point A to point B in real-space (target a hidden object)

At the same time need to tap the speaker icon at a dynamic rhythm (dual-task) for the executive functions test

Or tap the speaker icon while discriminating between a high-pitch target) and low pitch sound for the psychomotor processing speed test

↓

See it in Action

Using an augmented reality framework that allows performing tests on complex everyday tasks while directly interacting with a user's environment and thus physically activate him, we are testing three major areas:

The Science

Our goal: Discover cognitive outcomes prior to clinical onset

Clinical trials and public health intervention programs are currently hindered by the lack of cognitive outcome measurements prior to clinical onset, which may be used to evaluate efficacy at this early stage.

Working on our goal we focused on finding specific spatial tasks, which are likely to target brain areas prone to the earliest pathologic changes.

Our findings, later verified by independent research, suggest that midlife persons with increased risk for later life dementia already show some subtle cognitive changes principally in visuospatial functions rather than the functions most commonly currently used to investigate preclinical and prodromal AD [1].

At Altoida we have developed an instrumental activities of daily living (iADL) methodology based on longitudinal clinical studies with more than 2750 patients at risk over a period of 8+ years.

After taking an iPhone app based test for 10 minutes, published literature from 2750 patients suggest that neurological index measurements may assist physicians in predicting the onset of MCI/pAD on average of 6 years prior to clinical onset.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

More Informationclick to enlarge

Dementia causes

Early screening for AD

Current solutions

Scientific validation

Sensitivity & Specificity

Dashboard

Healthcare impact

Leadership: Medicine, Technology & Business Acumen

Ioannis Tarnanas

Founder & Chief Scientist (CSO)

PhD in Neuroscience; focus on Alzheimer’s and cognitive performance. 15 years research Dementia & Virtual Reality and previous track record in successful start-ups. Pioneered computational (functional) biomarkers for the early screening of AD as a low cost, internet delivered and non-invasive prognostic tool.

Adrian Locher

Founder & President of the Board

BA from University of St. Gallen (HSG) in Business and Economics is a serial entrepreneur and investor with focus on Artificial Intelligence. Previous to exiting an e-commerce firm at 100M revenue, he built several companies in the software space with clients like Facebook, Microsoft and NASA. He was awarded "HSG Entrepreneur of the Year 2012", "Swiss E-Commerce Champion 2015" and was ranked "40 under 40" by Swiss Bilanz magazine.

Advisors: Healthcare innovations, technology pioneers

Professor Brenda K. Wiederhold

Behavioral Health Advisor

PhD in Clinical Health Psychology; focus on development of Virtual Reality tools for the assessment and treatment of mental health disorders. 20 years success treatment patients with anxiety, stress, and phobias with virtual reality and biosensors. CEO of Interactive Media Institute, a 501c3 non-profit committed to improving access to mental healthcare services.

Dr. Mark D. Wiederhold

Medical Advisor

MD in Clinical Medicine, PhD in Anatomic and Clinical Pathology. 30 years of research focused on development of non-invasive biosensors and Virtual Reality therapy. Over 200 publications, on staff at Scripps Clinic for 15 years. Developed numerous digital technology tools to assess cognitive function in patients with TBI and PTSD.

Professor Elgar Fleisch

Strategic Advisor

Elgar Fleisch has a double appointment at ETH Zürich and University St. Gallen (HSG). At ETH, he is a full professor of information management, at HSG of technology management. His work focuses on applications, economic impacts, and infrastructures of mobile and ubiquitous computing.